Our Developmental Research Program will support both investigator-initiated individual pilot project applications as well as targeted pilot projects in specific areas of research that are highly likely to advance the translational research goals of the SPORE. Investigator-initiated individual pilot project proposals will be received in response to an annual request for proposals. These proposals may also be received for consideration at any time if the potential impact of the research is extremely high and of a timely nature. The targeted pilot projects involve: (1) individual pilot projects and (2) inter-institutional pilot projects. The general criteria for pilot project selection include the level of creativity and/or evidence of a clear contribution toward the success of our translational research objectives and completion of the long-term research goals of the SPORE. The ongoing solicitation process for Developmental Research Funds has been successful since the inception of the Baylor SPORE. The Scientific Advisory Committee, under the direction of Bert W. O'Malley, M.D., has major responsibility for evaluating, prioritizing and awarding all developmental research funding. Reviews will occur on a yearly basis after the solicitation process. Provisions will be made for funding extraordinary and timely individual pilot projects on an ad hoc basis. Provisions will also be made for evaluating, prioritizing and awarding targeted research initiatives. The assessment of progress of all Developmental Research Program funded projects involves informed discussion during translational steering group meetings, presentations at SPORE investigator's meetings, at the Baylor SPORE Annual Scientific meeting, and from annual written reports that are reviewed by the Scientific Advisor's Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058204-09
Application #
6611124
Study Section
Project Start
2002-07-15
Project End
2007-05-31
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications